Data +Oct 23, 2026
Positive data — Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA…▸
high impact
Data +Sep 24, 2026
Positive data — Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis▸
high impact
Data +Sep 23, 2026
Positive data — Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs▸
high impact
Data +Sep 22, 2026
Positive data — Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advan…▸
high impact
Data +Sep 11, 2026
Positive data — BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)▸
high impact
Data −Sep 08, 2026
Negative data — Market-Moving News for September 8th▸
high impact
ApprovalSep 07, 2026
FDA approval — Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease - Slid…▸
high impact
ApprovalSep 04, 2026
FDA approval — Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment▸
high impact
Data −Sep 04, 2026
Negative data — Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) an…▸
high impact
ApprovalAug 28, 2026
FDA approval — Could Ionis Pharmaceuticals (IONS) Stock Become a Biotech Powerhouse as its Commercial Pipeline Takes Off?▸
high impact
EarningsJul 29, 2026
Q2 2026 report+0.8%muted
EarningsApr 29, 2026
Q1 2026 report+0.8%muted
EarningsFeb 25, 2026
FY 2025 report+1.3%muted
EarningsJan 12, 2026
FY 2025 report-5.4%negative
EarningsOct 29, 2025
Q3 2025 report+2.5%muted
EarningsJul 30, 2025
Q2 2025 report+0.2%muted
EarningsApr 30, 2025
Q1 2025 report+9.6%positive
EarningsFeb 19, 2025
FY 2024 report+0.3%muted
EarningsNov 06, 2024
Q3 2024 report-0.4%muted